# The Effect of Memantine on Functional Outcomes and Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis (ALS)

> **NCT00409721** · PHASE2 · COMPLETED · sponsor: **University of Alberta** · enrollment: 42 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** Memantine

## Key facts

- **NCT ID:** NCT00409721
- **Lead sponsor:** University of Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2011-03-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00409721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00409721, "The Effect of Memantine on Functional Outcomes and Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-08-19 from https://api.ai-analytics.org/clinical/NCT00409721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*